ITMCTR2200006487
Not yet recruiting
未知
oncology
XiyuanHospital of CACMS0 sitesTBD
Conditionscolorectal cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- colorectal cancer
- Sponsor
- XiyuanHospital of CACMS
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) 18\-85 years old, regardless of gender;
- •(2\) It was pathologically diagnosed as colorectal cancer and its clinical stage was stage IV;
- •(3\) Patients who intend to receive the standard third\-line treatment of Western medicine or have begun to receive the third\-line treatment (no more than 14 days);
- •(4\) ECoG 0\-2 points;
- •(5\) Estimated survival period \= 3 months;
- •(6\) Measurable lesions meeting RECIST 1\.1 standard;
- •(7\) No strict center of gravity, abnormal lung, liver and kidney functions;
- •(8\) Normal coagulation function, no active bleeding and thrombosis;
- •(9\) Voluntarily join the study and sign the informed consent form;
- •(10\) It is expected that the patients with good compliance can follow up the efficacy and adverse reactions according to the protocol requirements.
Exclusion Criteria
- •(1\) Patients with brain metastases with clinical symptoms;
- •(2\) Combined with other untreated malignant tumors;
- •(3\) Patients with dmmr by immunohistochemistry or MSI\-H by gene detection;
- •(4\) Patients with uncontrollable hypertension who cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure \= 140mmhg/ diastolic blood pressure \= 90mmHg);
- •(5\) Suffering from uncontrolled cardiac clinical symptoms or diseases, such as a.nyha II and above heart failure; b. Unstable angina pectoris; c. Myocardial infarction occurred within 1 year; d. Patients with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;
- •(6\) There are many factors that affect the absorption of oral drugs, such as inability to swallow and intestinal obstruction;
- •(7\) Patients at risk of bleeding, including the following: A. active peptic ulcer lesions; b. Those with history of melena and hematemesis within 3 months; c. Hemoptysis occurred within 1 month before entering the study;
- •(8\) Patients with thrombotic diseases or receiving anticoagulant drugs; Long term anticoagulation therapy with warfarin or heparin or long\-term antiplatelet therapy (aspirin \= 300 mg/ day or clopidogrel \= 75 mg/ day) is required;
- •(9\) Major surgery, open biopsy or significant trauma were performed within 28 days before enrollment;
- •(10\) Patients who will or are participating in other clinical trials;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Communication Skills Training for Oncology Health Professionals working with Culturally and Linguistically Diverse Patientshealth communicationCancer - Any cancerPublic Health - Health service researchACTRN12613000560796niversity of New South Wales142
Completed
Not Applicable
CancerCOVID - Allocating resources for cancer care in times of the Sars-CoV-2 outbreak. Evidence and ethical implicationsColorectal cancer, pancreatic cancercoronary heart disease, diabetes mellitus, multiple sclerosisDRKS00026043Institut für Geschichte und Ethik der Medizin, Martin-Luther-Universität Halle-Wittenberg272
Recruiting
Not Applicable
The diagnosis of malignacy and treatment protocolin hepatocellular carcinoma ; The establish of method by 18F-fluorodeoxyglucose-positron emission tomography-computed tomographyJPRN-UMIN000007146Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine45
Completed
Not Applicable
Oncologic Outcome and Quality of Life of patients with node negative vulvar cancer after sentinel node biopsy or systematic inguino-femoral lymphadenectomy - an epidemiological investigatioC51Malignant neoplasm of vulvaDRKS00013298Evangelisches Krankenhaus Kalk97
Completed
Not Applicable
Cancer Research Campaign trial for the treatment of women with early breast cancer: the role of local prophylactic radiotherapyBreastCancerISRCTN65764657Cancer Research UK (CRUK) (UK)